However, since the complete absence of immunolabeling or IHC overexpression for p53 (≥ 50% positive cells) has been found to closely correlate with the presence of TP53 mutations in several tumor types [31–35], p53 protein expression, as determined by IHC, was used as surrogate for TP53 mutation status. This evidence concerns the gene TP53 and neoplasm.